NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $535,000 | +41212.7% | 500,000 | 0.0% | 0.03% | -53.3% |
| Q2 2023 | $1,295 | -36.5% | 500,000 | 0.0% | 0.06% | -40.0% |
| Q1 2023 | $2,040 | -99.9% | 500,000 | 0.0% | 0.10% | -24.2% |
| Q4 2022 | $2,510,000 | -61.6% | 500,000 | 0.0% | 0.13% | -64.1% |
| Q3 2022 | $6,540,000 | +2.0% | 500,000 | 0.0% | 0.37% | -9.4% |
| Q2 2022 | $6,410,000 | -15.9% | 500,000 | 0.0% | 0.41% | +3.6% |
| Q1 2022 | $7,625,000 | -13.9% | 500,000 | 0.0% | 0.39% | +14.0% |
| Q4 2021 | $8,855,000 | -15.7% | 500,000 | 0.0% | 0.34% | -6.3% |
| Q3 2021 | $10,510,000 | +6.6% | 500,000 | 0.0% | 0.37% | +5.5% |
| Q2 2021 | $9,860,000 | – | 500,000 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |